Current role
Jason Ryan
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Jason Ryan
Jason Ryan is recorded as Chairman at GeneDx Holdings Corp. (WGS). Jason Ryan was last confirmed as Board Member at Dianthus Therapeutics, Inc. /DE/ (DNTH) in a filing dated April 24, 2020. The proxy statement of GeneDx Holdings Corp. reports total compensation of $441,470 for Jason Ryan in fiscal 2024, including a base salary of $6,490. Disclosed compensation is on record for 4 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Centerpoint Energy Inc (CNP)
Source not stated
Current -
Current
Start not stated–present
-
2021-01-01–2025-04-30
Last confirmed by a filing; no departure on record
-
Start not stated–2020-04-24
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Centerpoint Energy Inc
Other people whose current roles at this company are on record from its filings.
- Jason P. Wells CEO, CFO, COO, Board Member
- John W. Somerhalder II CEO
- Martin H. Nesbitt Chairman
- Christopher A. Foster CFO
- Kristie L. Colvin CFO, Chief Accounting Officer
- William D. Rogers CFO
- Jesus Soto, Jr. COO
- Monica Karuturi General Counsel
- Kara Gostenhofer Ryan Chief Accounting Officer
- Russell K. Wright Chief Accounting Officer
Leadership on record at GeneDx Holdings Corp.
Other people whose current roles at this company are on record from its filings.
- Eric Schadt CEO, Board Member
- Katherine Stueland CEO, Board Member
- Kevin Feeley CFO
- Richard Miao CFO
- Bryan Dechairo COO
- Bryan Dechairo, Ph.D. COO
- Daniel Clark General Counsel
- Dennis Charney Board Member
- Dr. Emily Leproust Board Member
- Dr. Sean George Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | GeneDx Holdings Corp. (WGS) | Board Chair | $6,490 | $441,470 |
| 2023 | GeneDx Holdings Corp. (WGS) | Chairman of the Board | $343,471 | $992,464 |
| 2022 | GeneDx Holdings Corp. (WGS) | Chairman of the Board | $510,923 | $3,193,461 |
| 2019 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | Chief Operating and Financial Officer | $398,485 | $1,940,724 |
Recent activity
No call appearances or filed executive changes recorded yet.